Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Hernia ; 26(3): 831-837, 2022 06.
Artigo em Inglês | MEDLINE | ID: mdl-35028731

RESUMO

BACKGROUND: The choice of how to repair inguinal hernias in adolescents has historically been a matter of experience and differed between pediatric surgeons who traditionally performed a high ligation of the sac and general surgeons who typically perform a repair using mesh. This up-to-date review thoroughly examines the subject and discusses the suitability of both types of repairs in this unique age group. METHODS: A 20-year Pub Med search was performed for the following terms: adolescent hernia repair including reports of mesh hernia repair in adolescents and postoperative complications including chronic inguinal pain and recurrences. RESULTS: The evidence in the literature suggests that while there appears to be no difference between the two types of repairs with regards to recurrence and complications, changes in the pelvic floor physiology in adolescents suggest that a selective, individualized approach can be recommended depending on the size and nature of the presenting pathology. CONCLUSIONS: A selective approach to the inguinal hernia in adolescent patients based on the size of the defect appears justified.


Assuntos
Dor Crônica , Hérnia Inguinal , Laparoscopia , Adolescente , Criança , Dor Crônica/cirurgia , Virilha/cirurgia , Hérnia Inguinal/complicações , Hérnia Inguinal/cirurgia , Herniorrafia/efeitos adversos , Humanos , Laparoscopia/efeitos adversos , Complicações Pós-Operatórias/etiologia , Recidiva , Telas Cirúrgicas/efeitos adversos , Resultado do Tratamento
2.
Int J Med Robot ; 7(1): 27-32, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21341360

RESUMO

BACKGROUND: The robotic approach is an interesting option for overcoming the limitations of laparoscopic adrenalectomy. We aimed to report our technique and outcomes of robot-assisted adrenalectomy (RAA). METHODS: From November 2000 to February 2010, all consecutive patients who underwent a RAA by the same surgeon were prospectively entered into a dedicated database. The data were reviewed retrospectively. RESULTS: During the study period, 21 right (50%), 20 left (47.6%) and 1 bilateral (2.4%) RAA were performed. Mean lesion size was 5.5 cm (max. 10 cm). Mean operative time was 118 ± 46 min and median blood loss was 27 ml. There were no conversions. The postoperative morbidity rate was 2.4%; mortality rate, 2.4%; median hospital stay, 4 days. CONCLUSIONS: RAA achieves good short-term outcomes and could be considered a valid option for the treatment of adrenal masses, with the potential to expand the limits of minimally invasive surgery.


Assuntos
Neoplasias das Glândulas Suprarrenais/mortalidade , Neoplasias das Glândulas Suprarrenais/cirurgia , Adrenalectomia/mortalidade , Laparoscopia/mortalidade , Robótica/estatística & dados numéricos , Cirurgia Assistida por Computador/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Illinois/epidemiologia , Masculino , Pessoa de Meia-Idade , Prevalência , Medição de Risco , Fatores de Risco , Análise de Sobrevida , Taxa de Sobrevida , Resultado do Tratamento
4.
Acta Neurochir (Wien) ; 138(2): 215-20, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-8686548

RESUMO

The object of this study is to evaluate the efficacy of a high dose of carboplatin in 20 patients operated on for high grade glioma (Group A) compared with a matched control (Group B) treated with BCNU administered after radiotherapy. The toxicity profile has been evaluated during the therapy. The survival of patients entering this study was measured in terms of months: the mean survival time was 10.45 months and the median 11.0 months in the group treated with carboplatin (8 patients are still alive); the 18-month survival rate was 10%. The mean survival time of the control group was 9.85 months and the median 10.5 months; no patients are still alive and the 18-month survival rate was 0%. On the basis of our phase II clinical study, we could conclude that i.v. administration of high-doses of carboplatin in high grade gliomas is generally well tolerated and the results are better than those of a matched control treated with 1-2 courses of BCNU (low-dose). The adjuvant treatment and the role of carboplatin in the therapy of high grade gliomas is discussed.


Assuntos
Antineoplásicos/administração & dosagem , Astrocitoma/tratamento farmacológico , Neoplasias Encefálicas/tratamento farmacológico , Carboplatina/administração & dosagem , Glioblastoma/tratamento farmacológico , Adulto , Idoso , Antineoplásicos/efeitos adversos , Astrocitoma/mortalidade , Astrocitoma/radioterapia , Astrocitoma/cirurgia , Neoplasias Encefálicas/mortalidade , Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/cirurgia , Carboplatina/efeitos adversos , Carmustina/administração & dosagem , Carmustina/efeitos adversos , Quimioterapia Adjuvante , Terapia Combinada , Irradiação Craniana , Relação Dose-Resposta a Droga , Feminino , Seguimentos , Glioblastoma/mortalidade , Glioblastoma/radioterapia , Glioblastoma/cirurgia , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Radioterapia Adjuvante , Taxa de Sobrevida , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...